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Rhône-Poulenc S.A.
What is it famous for? Rhône-Poulenc
ranks among the world’s top ten
chemical and pharmaceutical
companies, with operations in 160
countries. In France, its home
country, Rhône-Poulenc is very
much a household name. But within
the next few weeks, if all goes
according to plan, Rhône-Poulenc
will be no more.
What will happen to it? The
pharmaceuticals and agricultural
parts of Rhône-Poulenc are in the
final stages of being merged with
those of Germany’s Hoechst. The
new company, Aventis, looks set to
become the world’s largest life science
company, with combined sales of
US$20 billion and 95,000 employees
worldwide. (The Rhône-Poulenc
chemicals business will be spun off
following the merger.)
How did it begin? Etienne Poulenc, a
pharmacist, bought a Parisian
apothecary in 1858. He was joined by
his two brothers in 1900 and the
business, which became known as
Etablissement Poulenc Frères,
started producing drugs, notably
arsenobenzol, a treatment for
syphilis. In 1927, starting what has
turned into a company tradition, the
Poulenc brothers bought a large slice
of the British company May & Baker
(whose claim to fame is discovering a
sulfamide drug once used to cure
Winston Churchill of pneumonia).
The name Rhône-Poulenc was first
used in 1928 following a merger with
the chemical company Société
Chimique des Usines du Rhône.
How did it come to be so big? Through
one acquisition after another. In 1968,
Rhône-Poulenc bought a controlling
stake in Institut Mérieux, a vaccine
business founded by Marcel
Mérieux, a former assistant to Louis
Pasteur. In 1989, through Institut
Mérieux, Rhône-Poulenc succeeded
— in the face of stiff competition
from Ciba-Geigy — in persuading
the Canadian government to part
with Connaught Biosciences for
US$800 million. Connaught is
Canada’s largest vaccine producer. A
year later, Rhône-Poulenc acquired
US pharmaceuticals maker Rorer
and, in 1994, it took over Fisons, a
British drug company known for its
asthma and allergy treatments.
So, it’s gone from strength to strength?
Not exactly. In 1982, the newly
elected government of Francois
Mitterand took control of
Rhône-Poulenc in an attempt to arrest
the company’s decline, brought about,
some say, by poor management. With
the 39-year-old whiz, Loïk Le Floch-
Prigent, at the helm, the company
returned to profitability. It was during
this time that research was made a
priority at Rhône-Poulenc, no doubt
reflecting the background of Le
Floch-Prigent, a former researcher at
the industry ministry. The company
remained in government hands until
it was privatized again in 1993. This
year, though, its earnings took a 63%
dip as the company had to set aside
US$105 million for charges linked to
its merger with Hoechst and potential
litigation costs arising from a vitamin
price-fixing scandal.
What was the scandal about?
According to US anti-trust
investigators, executives of Roche,
BASF and Rhône-Poulenc met
secretly every year during the 1990s
to carve up the world’s vitamin
market, setting prices to the cent.
Roche and BASF were together
fined a record US$725 million; the
former president and the director of
worldwide marketing of Roche’s
vitamins division were both jailed
this year. Although Rhône-Poulenc
forged an amnesty deal by supplying
US prosecutors with evidence that
cracked the cartel, the company faces
lawsuits in the US from business
customers and consumers.
What’s it like to work there?
Rhône-Poulenc is considered one of
the best employers in France — in
terms of pay and benefits, not to
mention the excellent French wine
served in its subsidized cafeterias.
Although Rhône-Poulenc is
undoubtedly serious about its
business, its seemingly
no-holds-barred entertainment and
travel budget is the envy of many. It
remains to be seen whether the
arrival of the Germans will change
things. Already, doubts have been
expressed about the practicalities of
forging a Franco–German work
culture. Witness the reception in
Strasbourg last December to mark
the unveiling of the merger, when
relaxed, chain-smoking
Rhône-Poulenc executives rubbed
shoulders with their more formal
Hoechst counterparts.
Isn’t there a Rhône-Poulenc prize? Yes.
Rhône-Poulenc is known by readers
of popular science for its £10,000
book prize, awarded annually to the
non-fiction book judged to
contribute most to the public
understanding of science. Past
winners include media-friendly
scientists such as Stephen Jay Gould,
Jared Diamond and Steve Jones. The
Royal Society, which administers the
prize, says the award will carry on but
probably under a new name.
